[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nivolumab\" }]"}]},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The second PD-1 blocker, often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.\"","after":"\"Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.\""}]}]